Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women (PROMOTE-PIs)
Read time: 1 mins
Last updated:8th Oct 2009
This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell counts at high risk of malaria. The study is designed to test the hypothesis that pregnant women receiving a PI-based ART regimen will have lower risk of placental malaria compared to pregnant women receiving a non-PI based ART regimen. The primary study endpoint of the study is placental malaria.
|Study start date||2009-10-08|